...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Physiology and Biochemistry >Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure
【24h】

Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure

机译：循环miR-​​30d可以预测急性心力衰竭患者的生存率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background/Aims: Identification of novel biomarkers to identify acute heart failure (AHF) patients at high risk of mortality is an area of unmet clinical need. Recently, we reported that the baseline level of circulating miR-30d was associated with left ventricular remodeling in response to cardiac resynchronization therapy in advanced chronic heart failure patients. However, the role of circulating miR-30d as a prognostic marker of survival in patients with AHF has not been explored. Methods: Patients clinically diagnosed with AHF were enrolled and followed up for 1 year. Quantitative reverse transcription polymerase chain reactions were used to determine serum miR-30d levels. The univariate logistic regression analysis and multivariate logistic regression analysis were used to determine the predictors for all-cause mortality in AHF patients. Kaplan-Meier survival analysis was used to analyze the role of miR-30d in prediction of survival. Results: A total of 96 AHF patients were enrolled and followed up for 1 year. Serum miR-30d was significantly lower in AHF patients who expired in the one year follow-up period compared to those who survived. Univariate logistic regression analysis yielded 18 variables that were associated with all-cause mortality in AHF patients, while the multivariate logistic regression analysis identified 4 variables including heart rate, hemoglobin, serum sodium, and serum miR-30d level associated with mortality. ROC curve analysis showed that hemoglobin, heart rate and serum sodium displayed poor prognostic value for AHF (AUCs not higher than 0.700) compared to miR-30d level (AUC = 0.806). Kaplan-Meier survival analysis confirmed that patients with higher serum miR-30d levels had significantly lower mortality (P=0.001). Conclusion: In conclusion, this study shows evidence for the predictive value of circulating miR-30d as 1-year all-cause mortality in AHF patients. Large multicentre studies are further needed to validate our findings and accelerate the transition to clinical utilization.
机译：> 背景/目标： 鉴定新颖的生物标志物以鉴定具有高死亡风险的急性心力衰竭（AHF）患者是临床需求尚未得到满足的领域。最近，我们报道，在晚期慢性心力衰竭患者中，循环miR-​​30d的基线水平与心脏再同步治疗引起的左心室重塑有关。但是，尚未探讨循环miR-​​30d作为AHF患者生存的预后标志物的作用。 方法： 纳入临床诊断为AHF的患者，并随访1年。定量逆转录聚合酶链反应用于确定血清miR-30d水平。单因素logistic回归分析和多元logistic回归分析用于确定AHF患者全因死亡率的预测因子。 Kaplan-Meier生存分析用于分析miR-30d在预测生存中的作用。 结果： 总共招募了96名AHF患者，并进行了1年的随访。在一年的随访期内死亡的AHF患者的血清miR-30d显着低于存活的患者。单变量logistic回归分析产生了与AHF患者全因死亡率相关的18个变量，而多元logistic回归分析则确定了与死亡率相关的4个变量，包括心率，血红蛋白，血清钠和血清miR-30d水平。 ROC曲线分析显示，与miR-30d水平（AUC = 0.806）相比，血红蛋白，心率和血清钠显示出不良的AHF预后价值（AUC不高于0.700）。 Kaplan-Meier生存分析证实，血清miR-30d水平较高的患者死亡率显着降低（P = 0.001）。 结论： 总之，本研究显示了循环miR-​​30d作为AHF患者1年全因死亡率的预测价值的证据。还需要进行大型的多中心研究，以验证我们的发现并加速向临床应用的过渡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号